177Lu-PSMA-617 + Radiation Therapy for Prostate Cancer

This trial tests a new treatment for men with high-risk localized prostate cancer. It aims to determine if adding a drug called 177Lu-PSMA-617 (a targeted radioligand therapy) to standard radiation therapy and a shorter hormone treatment can enhance safety and reduce side effects. Participants will receive either this new combination therapy or the usual treatment with longer hormone therapy. Men diagnosed with high-risk prostate cancer, such as those with a PSA level over 20 or specific tumor characteristics, and who have not undergone prior prostate cancer treatment, might be suitable candidates for this trial. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify if you need to stop taking your current medications. However, it does mention that you cannot participate if you are receiving other investigational agents or are part of a concurrent treatment protocol involving radiotherapy, surgery, or systemic anti-cancer agents.

Studies have shown that 177Lu-PSMA-617 is generally safe for people. In one study, patients received doses of 177Lu-PSMA-617 and experienced few serious side effects. The most common side effects included tiredness, dry mouth, and nausea, occurring in more than 20% of patients.

Most treatments for prostate cancer, such as external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT), focus on targeting cancer cells generally or reducing hormone levels that fuel cancer growth. But 177Lu-PSMA-617 works differently, targeting a specific protein called PSMA found on prostate cancer cells, allowing for a more directed attack on the cancer. This precision means that 177Lu-PSMA-617 can potentially minimize damage to healthy cells, which is a big improvement over existing treatments. Researchers are excited because this approach not only promises to be more effective but might also reduce side effects associated with broader cancer therapies.

Research has shown that 177Lu-PSMA-617 effectively treats prostate cancer. In this trial, participants in Arm A will receive 177Lu-PSMA-617 combined with EBRT and 6 months of ADT. Studies have demonstrated that this treatment, when used with standard care, helps patients live longer and slows disease progression. About half of the patients experienced a significant drop in PSA levels, markers used to track prostate cancer. Real-world data indicates that patients typically go about 13.5 months without disease progression. Additionally, it has proven safe for patients. This suggests that 177Lu-PSMA-617 could be a promising option for managing prostate cancer.³⁴⁶⁷⁸